To assess health related quality of life (HRQoL), anxiety and depression symptoms and identify variables associated with them in patients with TKI-resistant CML receiving olverembatinib-therapy
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Olverembatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 03 Oct 2024 New trial record